NCT07819214
Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI
StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Notable Start date pushed from Oct 2026 to Dec 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Rate of Undetectable Measurable Residual Disease (uMRD) at End of Treatment
Timeframe: 1 year
Secondary (1)
Number of Participants with Complete Remission (CR) by International Workshop on CLL (iwCLL) criteria
Arms and interventions
EpcoritamabExperimental
Given IV
Drugs: Epcoritamab
Sites
1 site in 1 country
- Chao Family Comprehensive Cancer Center, University of California, IrvineOrange, California, United States